Investing Center Preview – Manage your investments and watch your net worth grow.
GMAB:NASDAQ – Large Cap Stock ()
Genmab A/S – GMAB Stock Overview
Last Price | Today's Change | 52-Week Range | Trading Volume |
---|---|---|---|
18.39 | -0.85 (-4.42%) | 18.30 - 30.50 | 2.5 million (Above Avg) |
Market data as of 4:00PM 04/04/25. Quotes are delayed by at least 15 min.
Overview - GMAB
Open | 18.80 |
---|---|
Previous Close | 19.24 |
Day's Range | 18.30 - 18.89 |
Market Cap | 12.2B |
Avg Volume (10 Day) | 1.5M |
Price/Earnings (Trailing 12 Mo.) | 11.0x |
Earnings Per Share (Trailing 12 Mo.) | 3.1474 |
Dividend Yield | No Dividend |
One-Click Scorecard - GMAB


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
Performed well consistently? | Neutral |
---|---|
Avoids excess debt? | Neutral |
Converting sales to profits? | Neutral |
Shareholder's money handled rationally? | Neutral |
Increased shareholder value? | Neutral |
Consistently increased owner earnings? | Neutral |
Sells at 25% discount to intrinsic value? | Neutral |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
Pays a cash dividend? | Neutral |
---|---|
Room to increase dividends? | Neutral |
Increased earnings over time? | Neutral |
Borrows within reasonable limits? | Neutral |
Stock is undervalued? | Neutral |
Have investors caught on? | Neutral |
Has support of institutional investors? | Neutral |
Has sufficient liquidity? | Neutral |
Latest Headlines - GMAB
TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer
Business Wire - Monday 03/31/2025 11:20 AM ET
TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy
Business Wire - Thursday 03/27/2025 8:00 AM ET
Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer
Business Wire - Monday 03/17/2025 12:19 PM ET
Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38
Business Wire - Monday 03/10/2025 10:21 AM ET
Industry Position - GMAB
GMAB | Industry Range | |
---|---|---|
Revenue Growth (1yr) | 30.67% | |
Net Income Growth (1yr) | 80.24% | |
Total Debt/Equity | 0.03 | |
LT Debt/Equity | 0.03 | |
Earnings Yield | 9.12% | |
Price/Sales | 3.99 |
Competitors - GMAB
Company | Last | Change |
---|
Data is delayed by at least 15 min.